Bridgefront Capital, LLC Iovance Biotherapeutics, Inc. Transaction History

Bridgefront Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.3 - $8.89 $70,191 - $189,090	21,270 New	21,270 $172,000
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $213,059 - $316,700	38,528 New	38,528 $235,000
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $191,106 - $250,082	-9,391 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$16.33 - $33.07 $37,346 - $75,631	-2,287 Reduced 19.58%	9,391 $244,000
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $334,808 - $614,146	11,678 New	11,678 $370,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.